Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fenuflakes is a proprietary, debittered, and defatted food ingredient derived from fenugreek seeds (*Trigonella foenum-graecum*), developed by Indus Biotech (Indus Group). It is characterized by a high-protein, high-fiber, and ultra-low-carbohydrate nutritional profile. Marketed as a nutraceutical and dietary supplement, it is intended for oral consumption to help manage blood sugar levels and improve insulin sensitivity, particularly in individuals with type 2 diabetes. The product functions by reducing the Glycemic Index (GI) of foods it is integrated into and supporting intestinal health through its combination of soluble and insoluble fibers. It is designed to be neutral in taste, allowing for easy integration into a variety of food products to enhance their nutritional value.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Fenuflakes.